Global pharmaceuticals group Novartis said today its bone cancer drug Zometa was granted a positive opinion by the EU's Committee for Proprietary Medicinal Products.
The company, which employs 460 people in the Republic, said its application for Zometa is based on data from three international trials on more than 3,000 patients.
Zometa, which is designed to treat bone decay in a variety of advanced tumours, was granted FDA approval for tumour treatment in February. The drug posted first quarter sales of 112 million Swiss francs.
The EU commission normally grants product approvals within a few months of a positive CPMP recommendation.
READ MORE
AFP